Evidence map›Paper›PMID 38205741›Full record

ReviewJournal of comparative effectiveness research2024

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers.

Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram Ramagopalan, Alind Gupta, Grace Hsu, Paul Arora, Vivek Subbiah

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Kristian ThorlundDept. Health Research Methods, Evidence, & Impact, McMaster University, ON, Canada.ORCID 0000-0001-5848-3111
Stephen DuffieldNational Institute for Health & Care Excellence, Manchester, UK.
Sanjay PopatRoyal Marsden Hospital, Imperial College, London, UK.ORCID 0000-0003-2087-4963
Sreeram RamagopalanLondon School of Economics, London, UK.ORCID 0000-0002-4766-5160
Alind GuptaCytel Inc., Waltham, MA, USA.
Grace HsuCytel Inc., Waltham, MA, USA.ORCID 0000-0001-7191-6612
Paul AroraDalla Lana School of Public Health, University of Toronto, ON, Canada.ORCID 0000-0001-6617-3631
Vivek SubbiahSarah Cannon Research Institute, TN, USA.ORCID 0000-0002-6064-6837
Cytel (United States) · USImpact · CALondon School of Economics and Political Science · GBNational Institute for Health and Care Excellence · GBRoyal Marsden Hospital · GBSarah Cannon · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of medicines in rare oncologic patient populations are growing, but well-powered randomized controlled trials are typically extremely challenging or unethical to conduct in such settings. External control arms using real-world data are increasingly used to supplement clinical trial evidence where no or little control arm data exists. The construction of an external control arm should always aim to match the population, treatment settings and outcome measurements of the corresponding treatment arm. Yet, external real-world data is typically fraught with limitations including missing data, measurement error and the potential for unmeasured confounding given a nonrandomized comparison. Quantitative bias analysis (QBA) comprises a collection of approaches for modelling the magnitude of systematic errors in data which cannot be addressed with conventional statistical adjustment. Their applications can range from simple deterministic equations to complex hierarchical models. QBA applied to external control arm represent an opportunity for evaluating the validity of the corresponding comparative efficacy estimates. We provide a brief overview of available QBA approaches and explore their application in practice. Using a motivating example of a comparison between pralsetinib single-arm trial data versus pembrolizumab alone or combined with chemotherapy real-world data for RET fusion-positive advanced non-small cell lung cancer (aNSCLC) patients (1-2% among all NSCLC), we illustrate how QBA can be applied to external control arms. We illustrate how QBA is used to ascertain robustness of results despite a large proportion of missing data on baseline ECOG performance status and suspicion of unknown confounding. The robustness of findings is illustrated by showing that no meaningful change to the comparative effect was observed across several 'tipping-point' scenario analyses, and by showing that suspicion of unknown confounding was ruled out by use of E-values. Full R code is also provided.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiasClinical ProtocolsHumansResearch Designcomparative efficacyexternal control armsquantitative bias analysisreal-world evidence

Identifiers

PMID38205741
PMCPMC10945419
OpenAlexW4390743877

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.